Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials

BACKGROUND: Primary and secondary resistance to imatinib, a selective receptor tyrosine kinase inhibitor (TKI), is a serious clinical problem in the control of advanced gastrointestinal stromal tumors (GIST). Here we report on a meta-analysis we performed to evaluate the efficacy of second-generatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Lile, Zhang, Zhongqiang, Yao, Hongliang, Liu, Kuijie, Wen, Yu, Xiong, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219427/
https://www.ncbi.nlm.nih.gov/pubmed/25378911
http://dx.doi.org/10.2147/DDDT.S63840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219427/
https://www.ncbi.nlm.nih.gov/pubmed/25378911
http://dx.doi.org/10.2147/DDDT.S63840

Ejemplares similares